Search results for " therapeutic"
Article
Discussing the Origins of the mRNA Therapeutics Field
Andy Geall, co-founder and chief development officer at Replicate Bioscience, discusses the historical context and buildup of the mRNA therapeutics field.
Watch video
Multimedia
Using mechanistic modeling in process development for advanced therapeutics
Peter Guterstam and Nick Whitelock discuss mechanistic modeling in process developemnt of advanced therapeutics.
MORE Q&As WITH INDUSTRY LEADERS >>
Article
Key Process Considerations for Therapeutic Oligonucleotides
Click here to read the article >>
Learn more about scalable solutions for developing and manufacturing oligonucleotide therapeutics.
Article
mRNA Therapeutics and Vaccines – Key Process Considerations
Click here >>
Learn more on key considerations and strategies for process development and scaling up in our new web hub for mRNA therapeutics and vaccines.
Article
Oligonucleotide Therapeutics Heading for Tons of Quantity in Annual Supply Need
Click here to read the full article >>
Solid-phase flow through technology poised to annually produce metric tons (1000 kg) provides the oligonucleotide therapeutic industry efficient synthesis t…
Article
Democratizing GMP Manufacturing for the New Therapeutic Pipeline
PharmTech Europe discusses technology that enables the “democratization” of mRNA manufacturing with Scott Ripley, general manager, Nucleic Acid Therapeutics and Precision Nanosystems, Cytiva, …
Article
eBook: Purification of Antibody Therapeutics - Approach for Diversified Pipeline
Antibody therapeutics are the largest class of biotherapeutics. Over the years, development beyond traditional monoclonal antibodies (mAbs) has increased. Today, we see multispecific and bispe…
Article
Accelerating the Development of mRNA Therapeutics
Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.
READ FULL ARTICLE >>
Article
Chromatography processes for the diversified therapeutic antibody pipeline
The diversity of antibody variants in today’s pipeline presents unique challenges for purification and we see molecules such as bsAbs, Fabs, dAbs, and others. Conventional chromatography protocols, …
Article
As the therapeutic pipeline diversifies, chromatography toolboxes are expanding.
Development beyond traditional monoclonal antibodies (mAbs) is increasing, and today, we see antibody variants like multispecific and bispecific antibodies and antibody fragments. In mAb proc…